Rectal Toxicity Articles

Contemporary methods of external beam radiotherapy for prostate cancer have reduced toxicity rates through beam modulation and image guidance, however, rectal injury has not been eliminated completely in this population.

Intensity-modulated radiation therapy (IMRT) is a major therapeutic option for localized prostate cancer. Image-guided radiation therapy (IGRT) allows tumor visualization and corrects the errors caused by daily internal movement of the prostate.

A major concern in prostate brachytherapy is rectal toxicity, which mainly depends on the dose and volume of rectum involved by radiation. We hypothesize that the rectal distension, as produced by constipation, influences the dosimetric parameters of the rectum and other pelvic organs.

We present long-term outcomes from a phase III randomized controlled trial that compared helical tomotherapy with three-dimensional conformal radiotherapy (3D-CRT) in the treatment of high-risk prostate cancer (PCa).

Rectal toxicity after prostate cancer (PCa) radiation therapy (RT) may be greater with protons compared with photon intensity-modulated RT, perhaps due to lateral penumbra and end-of-range uncertainty.

Recent clinical advances in radiation therapy have aimed to improve the therapeutic ratio through shortening the treatment duration through increasing the biologically effective dose (either through dose escalation or hypofractionation).

To develop a knowledge-based decision-support system capable of stratifying patients for rectal spacer (RS) insertion based on neural-network-predicted rectal dose, reducing the need for time- and resource-intensive radiotherapy (RT) planning.

The Vienna Rectoscopy Score (VRS; from 0, absence of rectal mucosal changes, to 5) assessed 1 year after radiotherapy is a surrogate end-point of late rectal toxicity. The aim of this study was to investigate the association between treatment-related factors and 1-year VRS.

We analyzed factors associated with rectal toxicity after iodine-125 prostate brachytherapy (BT) with or without external beam radiation therapy (EBRT).

In total, 2216 prostate cancer patients underwent iodine-125 BT with or without EBRT between 2003 and 2013.

The aim of the study was to evaluate toxicity after extremely hypofractionated radiotherapy (EHF-RT) using a non-isocentric robotic radiosurgery system for early stage prostate cancer.

Eligibility criteria of this feasibility study were 50 - 84 years old, and low-risk to intermediate-risk disease.

Dose escalation is now the standard of care for the treatment of prostate cancer with radiation therapy. However, the rectum tends to be the dose-limiting structure when treating prostate cancer, given its close proximity.

BERKELEY, CA (UroToday.com) - The application of a spacer to increase the distance between the prostate and the anterior rectal wall is an innovative technique helping to effectively protect the rectal wall.